Qube Research & Technologies LTD Rigel Pharmaceuticals Inc Transaction History

Qube Research & Technologies LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.12 - $1.57 $101,592 - $142,411	90,708 New	90,708 $134,000
Q3 2023 Nov 13, 2023	SELL	$1.07 - $1.39 $28,334 - $36,808	-26,481 Reduced 17.56%	124,331 $134,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $361,260 - $587,048	-322,554 Reduced 68.14%	150,812 $194,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $591,707 - $946,732	473,366 New	473,366 $624,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $634,266 - $7.03 Million	576,606 New	576,606 $680,000
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $75,043 - $357,295	-112,005 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$2.22 - $3.45 $20,399 - $31,702	9,189 Added 8.94%	112,005 $335,000
Q4 2021 Feb 01, 2022	SELL	$2.36 - $3.57 $20,373 - $30,819	-8,633 Reduced 7.75%	102,816 $272,000
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $322,266 - $414,342	92,076 Added 475.28%	111,449 $405,000
Q2 2021 Aug 13, 2021	SELL	$3.09 - $4.54 $221,899 - $326,026	-71,812 Reduced 78.75%	19,373 $84,000
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $166,652 - $245,252	49,747 Added 120.05%	91,185 $312,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $97,379 - $154,978	41,438 New	41,438 $145,000

355K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.8B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.